Masitinib with Riluzole for amyotrophic lateral sclerosis

Masitinib in combination with riluzole is in clinical development for the treatment of patients with
the amyotrophic lateral sclerosis (ALS), form of motor neurone disease (MND). ALS is a
progressive disease of the nervous system, where nerve cells in the brain and spinal cord that
control voluntary movement gradually deteriorate, causing loss of muscle function and paralysis.
ALS is a debilitating and life-threatening disease.